



# SAFETY DATA SHEET

Revision date 04-Oct-2022

Version 2

Page 1 / 11

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
**Product Code(s)** PZ03097  
**Trade Name:** Magnesium Sulfate in Water for Injection, USP  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as electrolyte replacement anticonvulsant

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous according to Regulation (EC) 1272/2008 and/or other applicable regulations.

### 2.2. Label elements

**Signal word** Not Classified

**Hazard statements** Not classified in accordance with international standards for workplace safety.

### 2.3. Other hazards

**Other hazards** An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
 Revision date 04-Oct-2022

Page 2 / 11

Version 2

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

**Section 3: COMPOSITION/INFORMATION ON INGREDIENTS**

**3.1 Substances**  
**Substances** Not applicable

**3.2 Mixtures**

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ SULPHURIC ACID ... % (CAS #: 7664-93-9)	**		231-639-5	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 5%<=C<15% Skin Corr. 1A :: C>=15% Skin Irrit. 2 :: 5%<=C<15%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	92	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
Magnesium sulfate heptahydrate (CAS #: 10034-99-8)	4-8		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 3 / 11

Version 2

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ SULPHURIC ACID ... % 7664-93-9	2140	No data available	0.375	No data available	No data available

## Additional information

+ Substance with a Union workplace exposure limit  
\*\* to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Move to fresh air. If discomfort persists, get medical attention.
<b>Eye contact</b>	Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
<b>Skin contact</b>	Wash skin with soap and water. If skin irritation persists, call a physician.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

**Most important symptoms and effects** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physicians** None.

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media** As for primary cause of fire.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical** Not applicable.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire. Emits oxides of sulfur under combustion.

### 5.3. Advice for firefighters

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 4 / 11

Version 2

**Special protective equipment for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

#### Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m<sup>3</sup>

ACGIH TLV

Ceiling: 2 mg/m<sup>3</sup>

Austria

2 mg/m<sup>3</sup>

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 5 / 11

Version 2

---

Bulgaria	STEL 4 mg/m <sup>3</sup>
Czech Republic	2.0 mg/m <sup>3</sup> 1 mg/m <sup>3</sup>
Denmark	Ceiling: 2 mg/m <sup>3</sup>
Estonia	Ceiling: 2 mg/m <sup>3</sup> 1 mg/m <sup>3</sup>
Finland	STEL: 2 mg/m <sup>3</sup>
France	Ceiling: 2 mg/m <sup>3</sup>
Hungary	2 mg/m <sup>3</sup> 1 mg/m <sup>3</sup>
Ireland	STEL: 2 mg/m <sup>3</sup>
Ceiling Limit Value	STEL: 2 mg/m <sup>3</sup>
Latvia	2 mg/m <sup>3</sup>
Poland	0.5 mg/m <sup>3</sup> STEL: 1 mg/m <sup>3</sup>
Romania	0.5 mg/m <sup>3</sup> 1 mg/m <sup>3</sup>
Slovakia	STEL: 3 mg/m <sup>3</sup>
Spain	2 mg/m <sup>3</sup>
Switzerland	STEL: 2 mg/m <sup>3</sup>
OSHA PEL	2 mg/m <sup>3</sup>
United Kingdom	(vacated) Ceiling: 2 mg/m <sup>3</sup> STEL: 2 mg/m <sup>3</sup>
<b>+ SULPHURIC ACID ... %</b>	
ACGIH TLV	0.2 mg/m <sup>3</sup>
Austria	0.1 mg/m <sup>3</sup> STEL 0.2 mg/m <sup>3</sup>
Bulgaria	0.05 mg/m <sup>3</sup>
Czech Republic	1 mg/m <sup>3</sup> 0.05 mg/m <sup>3</sup>
Denmark	Ceiling: 2 mg/m <sup>3</sup>
Estonia	0.05 mg/m <sup>3</sup>
European Union	0.05 mg/m <sup>3</sup>
Finland	TWA: 0.05 mg/m <sup>3</sup> 0.05 mg/m <sup>3</sup>
France	STEL: 0.1 mg/m <sup>3</sup>
Germany	0.05 mg/m <sup>3</sup> 0.1 mg/m <sup>3</sup>
Germany	Ceiling / Peak: 0.1 mg/m <sup>3</sup>
Hungary	0.1 mg/m <sup>3</sup>
Ireland	0.05 mg/m <sup>3</sup>
Italy	0.05 ppm
Ceiling Limit Value	STEL: 0.15 ppm
Latvia	0.05 mg/m <sup>3</sup>
Netherlands	1 mg/m <sup>3</sup>
Poland	0.05 mg/m <sup>3</sup>
Romania	0.05 mg/m <sup>3</sup>
Russia	0.05 mg/m <sup>3</sup> MAC: 1 mg/m <sup>3</sup>
Slovakia	Skin
Spain	0.05 mg/m <sup>3</sup>
Switzerland	0.05 mg/m <sup>3</sup> 0.1 mg/m <sup>3</sup>
OSHA PEL	STEL: 0.2 mg/m <sup>3</sup> 1 mg/m <sup>3</sup> (vacated) TWA: 1 mg/m <sup>3</sup>

---

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 6 / 11

Version 2

United Kingdom

TWA: 0.05 mg/m<sup>3</sup>  
STEL: 0.15 mg/m<sup>3</sup>

## 8.2. Exposure controls

<b>Engineering controls</b>	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.
<b>Environmental exposure controls</b>	No information available.
<b>Personal protective equipment</b>	Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
<b>Eye/face protection</b>	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
<b>Hand protection</b>	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
<b>Skin and body protection</b>	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
<b>Respiratory protection</b>	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
<b>General hygiene considerations</b>	Handle in accordance with good industrial hygiene and safety practice.

## **Section 9: PHYSICAL AND CHEMICAL PROPERTIES**

### 9.1. Information on basic physical and chemical properties

<b>Physical state</b>	Liquid
<b>Color</b>	Colourless
<b>Odor</b>	No information available.
<b>Odor threshold</b>	No information available
<b>Molecular formula</b>	Mixture
<b>Molecular weight</b>	Mixture
<b>Property</b>	<b>Values</b>
<b>pH</b>	3.5-6.5
<b>Melting point / freezing point</b>	No data available
<b>Boiling point / boiling range</b>	No data available
<b>Flash point</b>	No information available
<b>Evaporation rate</b>	No data available
<b>Flammability (solid, gas)</b>	No data available
<b>Flammability Limit in Air</b>	
<b>Upper flammability limit:</b>	No data available
<b>Lower flammability limit:</b>	No data available

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 7 / 11

Version 2

Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

## 9.2. Other information

No information available

### 9.2.1. Information with regard to physical hazard classes

**Oxidizing properties** None

### 9.2.2. Other safety characteristics

No information available

## **Section 10: STABILITY AND REACTIVITY**

### 10.1. Reactivity

**Reactivity** No data available.

### 10.2. Chemical stability

**Stability** Stable under normal conditions.

### Explosion data

**Sensitivity to Mechanical Impact** No data available.

**Sensitivity to Static Discharge** No data available.

### 10.3. Possibility of hazardous reactions

**Possibility of hazardous reactions** No information available.

### 10.4. Conditions to avoid

**Conditions to avoid** None known.

### 10.5. Incompatible materials

**Incompatible materials** None known.

### 10.6. Hazardous decomposition products

**Hazardous decomposition products** Thermal decomposition products include. oxides of sulfur.

## **Section 11: TOXICOLOGICAL INFORMATION**

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** The information included in this section describes the potential hazards of the active ingredient(s).

**Known Clinical Effects:** Adverse effects associated with therapeutic use include flushing, sweating, decrease in blood pressure (hypotension), circulatory failure, central nervous system, depression.

**Acute toxicity** Based on available data, the classification criteria are not met.

**Serious eye damage/eye irritation** Based on available data, the classification criteria are not met.

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 8 / 11

Version 2

**Skin corrosion/irritation** Based on available data, the classification criteria are not met.  
**Respiratory or skin sensitization** Based on available data, the classification criteria are not met.  
**STOT - single exposure** Based on available data, the classification criteria are not met.  
**STOT - repeated exposure** Based on available data, the classification criteria are not met.  
**Reproductive toxicity** Based on available data, the classification criteria are not met.  
**Germ cell mutagenicity** Based on available data, the classification criteria are not met.  
**Carcinogenicity** Based on available data, the classification criteria are not met.  
**Aspiration hazard** Based on available data, the classification criteria are not met.

## Acute Toxicity: (Species, Route, End Point, Dose)

### Magnesium sulfate heptahydrate

Rat Oral LDmin. 5000 mg/kg  
Mouse Oral LDmin. 3000 mg/kg

### Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
Sodium hydroxide	= 325 mg/kg ( Rat )	= 1350 mg/kg ( Rabbit )	-
+ SULPHURIC ACID ... %	= 2140 mg/kg ( Rat )	-	= 0.375 mg/L ( Rat ) 4 h

## Irritation / Sensitization: (Study Type, Species, Severity)

### Sodium hydroxide

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Severe

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Magnesium sulfate heptahydrate

Fertility and Embryonic Development Rat Oral 450 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Magnesium sulfate heptahydrate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

## **Carcinogenicity**

See below The International Agency for Research on Cancer (IARC) and the United States National Toxicology Program (NTP) have classified 'occupational exposure to strong inorganic acid mists containing sulfuric acid' as a known human carcinogen. This classification applies only to sulfuric acid when generated as a mist. This classification is debated within the scientific community and there is disagreement as to whether or not a cause and effect relationship between cancer and 'occupational exposure to strong inorganic acid mists containing sulfuric acid' exists.

### + SULPHURIC ACID ... %

IARC Group 1 (Carcinogenic to Humans)  
NTP Known Human Carcinogen

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

### 11.2.2. Other information

**Other adverse effects** No information available.



# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 9 / 11

Version 2

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

**No information available**

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

#### **PBT and vPvB assessment**

Chemical name	PBT and vPvB assessment
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ SULPHURIC ACID ... %	The substance is not PBT / vPvB PBT assessment does not apply

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

### 12.7. Other adverse effects

No information available.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 10 / 11

Version 2

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

**UN number:** Not applicable  
**UN proper shipping name:** Not applicable  
**Transport hazard class(es):** Not applicable  
**Packing group:** Not applicable  
**Environmental Hazard(s):** Not applicable  
  
**Special precautions for user:** Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

**CERCLA/SARA Section 313 de minimus %** Not Listed  
**California Proposition 65** Not Listed  
**TSCA** Present  
**EINECS** 231-791-2  
**AICS** Present

Magnesium sulfate heptahydrate

**CERCLA/SARA Section 313 de minimus %** Not Listed  
**California Proposition 65** Not Listed  
**EINECS** Not Listed  
**AICS** Present

Sodium hydroxide

**CERCLA/SARA Section 313 de minimus %** Not Listed  
**Hazardous Substances RQs** 1000 lb  
**California Proposition 65** Not Listed  
**TSCA** Present  
**EINECS** 215-185-5  
**AICS** Present  
**Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)** Schedule 5  
Schedule 6

+ SULPHURIC ACID ... %

**CERCLA/SARA Section 313 de minimus %** 1.0 %  
**Hazardous Substances RQs** 1000 lb  
**California Proposition 65** carcinogen 3/14/2003  
**TSCA** Present  
**EINECS** 231-639-5  
**AICS** Present  
**Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)** Schedule 6

### European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

### Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ SULPHURIC ACID ... % - 7664-93-9	Use restricted. See item 75.	

# SAFETY DATA SHEET

Product Name Magnesium Sulfate in Water for Injection, USP (Hospira Inc.)  
Revision date 04-Oct-2022

Page 11 / 11

Version 2

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

**Data Sources:** Publicly available toxicity information.

**Reason for revision** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 10 - Stability and Reactivity. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

**Revision date** 04-Oct-2022

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**